AGXT2 Suppresses the Proliferation and Dissemination of Hepatocellular Carcinoma Cells by Modulating Intracellular Lipid Metabolism
DOI: https://doi.org/10.2147/jhc.s470250
2024-08-26
Journal of Hepatocellular Carcinoma
Abstract:Tian Chen, 1 Lunjian Xiang, 2 Wenjin Zhang, 3 Zhenyi Xia, 4, &ast Weixian Chen 1, &ast 1 Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 2 Hepatobiliary Surgery, Chongqing University Three Gorges Hospital, Chongqing, People's Republic of China; 3 Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, People's Republic of China; 4 Thoracic surgery, Chongqing University Three Gorges Hospital, Chongqing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Weixian Chen; Zhenyi Xia, Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjing Road, Yuzhong District, Chongqing, 400010, People's Republic of China, Tel +8613527526490, Fax +86-23-581045783, Email ; Purpose: Alanine glyoxylate aminotransferase (AGXT) family members are crucial in cancer processes, but their role in hepatocellular carcinoma (HCC) metabolism is unclear. This study investigates AGXT2's function in HCC. Patients and Methods: AGTX2 expression was studied using bioinformatics, real-time reverse transcriptase-polymerase chain reaction (RT-qPCR), Western blot, and Enzyme-linked immunosorbent assay (ELISA). A lentivirus-induced AGTX2 overexpression cell model was analyzed with RNA sequencing (RNA-seq) and liquid chromatography-mass spectrometry (LC-MS). Cholesterol levels were confirmed by Oil Red O staining. AGTX2 effects were evaluated through cell cycle analysis, wound healing, and transwell migration assays.Tumorigenic effects were observed in NOD-SCID IL2Rγnull (NTG) mice in subcutaneous experiments. Protein interaction was examined through co-immunoprecipitation methods. Results: We observed a significant reduction in AGXT2 mRNA and protein levels in both HCC tumor tissues and serum samples from patients with liver cancer, which was associated with a worse prognosis. The activation of AGXT2 has been shown to effectively decrease cholesterol levels in liver cancer cells, serving as an antagonist in the cholesterol metabolism pathway. An increase in low density lipoprotein receptor ( LDLR) mRNA was noted in cells overexpressing AGXT2, accompanied by a decrease in LDLR protein and an elevation in proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) mRNA and protein levels. Molecular docking and co-immunoprecipitation experiments further elucidated the interaction between AGXT2 and LDLR proteins. AGXT2 was observed to suppress the migratory and invasive capabilities of HCC cells, inducing cell cycle arrest in the G2/M phase. AGXT2 activation inhibited subcutaneous liver cancer tumor growth in NTG mice. Conclusion: AGXT2 was found to lower cholesterol levels in liver cancer cells, possibly through interactions with the LDLR protein and modulation of PCSK9-mediated LDLR degradation. This mechanism may impede cholesterol transport to liver cancer cells, thereby suppressing their growth and metastasis. Keywords: LDLR, PCSK9, cholesterol metabolic, biomarkers Liver cancer ranks as the sixth most prevalent malignancy globally. Approximately 841,000 new cases and 782,000 deaths are reported annually. 1 Hepatocellular carcinoma (HCC) is the final phase of chronic liver disease caused by nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2,3 The significant rise in steatosis and nonalcoholic steatohepatitis is a key contributor to the increased risk of HCC development due to metabolic disorders. 4 The worldwide occurrence of HCC is increasing due to its connection with high rates of obesity and type 2 diabetes. 5 Moreover, due to its rapid progression, many patients are found to be in the middle and late stages of the disease, resulting in a poor prognosis. Although some new metabolic therapy drugs have been developed, they have limited effectiveness due to patient specificity, 6 thus necessitating the search for new therapies. Tumors are seen as a combination of genetic disorders and metabolic disease, with mutations in regulatory genes playing a key role in cancer development and treatment resistance, 7 Recent studies suggest a link between metabolism and epigenetics, which can promote tumor growth. HCC exhibits metabolic changes in genes that support tumor growth and adaptation to harsh environments, with accentuated lipid metabolic reprogramming. 8 Lipid metabolic reprogramming is now a research focus in HCC, in addition to the well-known tumor-promo -Abstract Truncated-
oncology